Errata

Brenchley JM, Vinton C, Tabb B, et al. Differential infection patterns of CD4[+] T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. *Blood*. 2012;120(20):4172-4181.

On page 4180 in the 15 November 2012 issue, there is an error in the Acknowledgments. The second sentence of the Acknowledgments reads, "This work was supported by the Intramural National Institute of Allergy and Infectious Diseases, National Institutes of Health program, and the National Cancer Institute, National Institutes of Health (contract HHSN261200800001E and R01 AI-084836, M.P.)." The sentence should have read, "This work was supported by the Intramural National Institute of Allergy and Infectious Diseases, National Institutes of Health program, and the National Cancer Institute, National Institutes of Health (contract HHSN261200800001E, R37 AI-066998 [G.S.], and R01 AI-084836 [M.P.])."

Lamarque M, Raynaud S, Itzykson R, et al. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. *Blood*. 2012; 120(25):5084-5085.

On page 5084 in the 13 December 2012 issue, there are errors in Table 1. In the column "OS, mo," the entries corresponding to rows "<50" and ">100" are transposed, which suggests that patients with low platelet count had a longer survival than patients with high platelet count. The incorrect entries read "20.3" and "9.7," respectively. These 2 entries should have read "9.7" and "20.3," respectively. The corrected Table 1 is shown.

Table 1. Characteristics and outcome of MDS patients treated with AZA according to IPSS-R parameters

Variable	Percentage	Response according to IWG 2006[4]	P	OS, mo	P
Hemoglobin, g/dL					
<8	18%	44%	.948	8.1	.06
8-10	48%	42%		15.3	
>10	34%	44%		14.1	
Absolute neutrophil count, ×10^9/L					
<0.8	45%	45%	.465	15.3	.4
>0.8	54%	40%		12.2	
Platelet count, ×10^9/L					
<50	43%	40%	.10	9.7	.0001
50-100	32%	42%		15.1	
>100	25%	50%		20.3	
BM blasts, %					
≤2	2%	60%	.287	16.1	.12
3-5	3%	70%		8.1	
5-10	18%	44%		15.9	
>10	77%	41%		14.1	
Cytogenetic group					
Very good	1%		.646		.0001
Good	37%	46%		21.8	
Intermediate	18%	39%		12.3	
Poor	12%	45%		15.1	
Very poor	32%	38%		7.1	
IPSS-R classification					
Low	<1%		.463		.0001
Intermediate	11%	46%		30.7	
High	34%	47%		17.6	
Very high	55%	39%		10	

4. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. *Blood*. 2006;108(2):419-425.